Results 151 to 160 of about 584,870 (306)
Assessment of Clinical Hematology Laboratory Performance Using Sigma Metrics and Associated Factors in Total Testing Process at the Dessie Comprehensive Specialized Hospital, Northeast, Ethiopia: A Cross-Sectional Study. [PDF]
Mulatie Z +10 more
europepmc +1 more source
We developed a novel copper‐doped aluminum nano‐adjuvant (CuNA) to overcome cytarabine resistance in acute myeloid leukemia (AML). CuNA effectively sensitizes drug‐resistant AML cells to cytarabine by inducing mitochondrial dysfunction and inhibiting HMGCR/GPX4 to amplify ferroptosis.
Chao He +10 more
wiley +1 more source
Correction to: Significance of targeting DNMT3A mutations in AML. [PDF]
Huang G, Cai X, Li D.
europepmc +1 more source
This study develops a dual‐bioinspired hydrogel, MSA@PGel (macrophage membrane‐coated and salvianolic acid B/5‐aminolevulinic acid co‐loaded liposomes embedded in a polydopamine‐based gel), that integrates macrophage membrane‐mediated active targeting and mussel‐inspired wet adhesion for programmed intervention in oral precancerous lesions.
Xiaoxian Zhao +8 more
wiley +1 more source
Hematology clinicopathological exercise
Asmaa Mohammed Thanun
doaj +1 more source
ASH's commitment to SCD: building on 10 years of progress. [PDF]
Boucher AA +7 more
europepmc +1 more source
Three‐Dimensional Ovary Model to Improve and Study Murine Follicle Growth
To develop new methods for fertility preservation in women, novel culture systems for small follicles need to be established. In this work, a poly(ethylene glycol) based scaffold, with appropriate mechanical and bioactive features to support mouse follicle and ovary cell growth is developed, and the formed cell‐follicle interactions are visualized ...
Mira Jacobs +6 more
wiley +1 more source
Correction to: Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial. [PDF]
Jiang B +17 more
europepmc +1 more source
The biomimetic nanoplatform IMNP (ETS1 pDNA/PBAE@ITP‐MM) undergoes targeted disassembly at inflammatory vascular sites to release the ETS1 plasmid (pETS1). This release initiates a cascade of effects that inhibit pathogenic pathways and support immune homeostasis. (Abbreviations: EndMT, endothelial‐to‐mesenchymal transition; EC, endothelial cell; TC, T
Feng Zhang +13 more
wiley +1 more source
Real-world evidence of measurable residual disease assessment in multiple myeloma. [PDF]
Cedena MT +21 more
europepmc +1 more source

